AKTS
Aktis Oncology, Inc.
Next earnings ≈ Aug 3, 2026 · est. from filing cadence
Last earnings -1.8% on 2026-05-11
$31.76
▲ +5.48%$31.76▲ +41.79%
over 1Y
L $15.19H $32.23
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.5%
1W+2.0%
1M+56.8%
3M+82.8%
YTD+41.8%
1Y+41.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 12 analysts
Strong Buy
Mixed signals in the latest filings.
Aktis Oncology, Inc. shows limited reported revenue.
On these fundamentals, AKTS screens as SELL on the SEC figures.
Is AKTS a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 32 @ ~3.94 est
- Short put 29 @ ~2.45 est
debit $149max +$151max −$149BE 30.51
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Key statistics
Valuation
Enterprise value$1.76B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- 8-K Earnings results2026-05-11
- 10-Q Quarterly report2026-05-11
- 8-K Officer / director change2026-04-16
- 8-K Earnings results2026-03-30
- 10-K Annual report2026-03-30
- 8-K Charter / bylaws change2026-01-12
- S-1/A Securities registration2026-01-07
- S-1/A Securities registration2026-01-05
- S-1 Securities registration2025-12-19
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-05-14open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗4Period ending 2026-04-152026-04-16open ↗3Period ending 2026-04-152026-04-16open ↗8-KPeriod ending 2026-04-152026-04-16open ↗8-KPeriod ending 2026-03-302026-03-30open ↗10-KPeriod ending 2025-12-312026-03-30open ↗SCHEDULE 13DFiling2026-01-20open ↗SCHEDULE 13DFiling2026-01-20open ↗SCHEDULE 13DFiling2026-01-15open ↗3Period ending 2026-01-122026-01-15open ↗
Frequently asked
- Is Aktis Oncology, Inc. (AKTS) a buy?
- AKTS currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
Sources: SEC EDGAR (CIK 0002035832, latest 10-Q filed 2026-05-11) · EODHD · as of 7/5/2026, 12:32:53 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 8:32 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.